ABCMdb

PMID: 19414346

Katayama K, Shibata K, Mitsuhashi J, Noguchi K, Sugimoto Y
Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
Anticancer Res. 2009 Apr;29(4):1059-65., [PubMed]

Sentences

No. Mutations Sentence Comment

147 ABCG2 p.Gln141Lys The expression levels of BCRP gene products harboring a C421A (Q141K) SNP are 5-fold lower than those of the wild-type gene, and the resistance of cells with a C421A BCRP SNP to SN-38 is also 5-fold lower than those with wild-type BCRP (25, 27). Login to comment 148 ABCG2 p.Phe208Ser Cells containing a T623C (F208S) BCRP cDNA express only marginal levels of BCRP protein, and resistance to SN-38 is not observed (27). Login to comment 149 ABCG2 p.Gln141Lys ABCG2 p.Phe431Leu The expression levels of BCRP gene products harboring a C421A (Q141K) SNP are 5-fold lower than those of the wild-type gene, and the resistance of cells with a C421A BCRP SNP to SN-38 is also 5-fold lower than those with wild-type BCRP (25, 27). Login to comment 150 ABCG2 p.Phe208Ser Cells containing a T623C (F208S) BCRP cDNA express only marginal levels of BCRP protein, and resistance to SN-38 is not observed (27). Login to comment 151 ABCG2 p.Phe431Leu In addition, T1291C (F431L) BCRP-transfectants express two BCRP products of 65 kDa and 70 kDa, and resistance to SN-38 in these cells is significantly lower than wild-type BCRP-transfectants (27). Login to comment